Clinical Trials Logo

Carcinoma, Adenoid Cystic clinical trials

View clinical trials related to Carcinoma, Adenoid Cystic.

Filter by:

NCT ID: NCT06462183 Not yet recruiting - Colorectal Cancer Clinical Trials

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

Start date: June 2024
Phase: Phase 1
Study type: Interventional

Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRCT

NCT ID: NCT06322576 Not yet recruiting - Clinical trials for Adenoid Cystic Carcinoma

177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

Start date: July 2024
Phase: Phase 2
Study type: Interventional

This is a single arm trial with one Cohort for people with recurrent or metastatic adenoid cystic carcinoma that cannot be treated with surgery. 10 participants will be enrolled in Cohort 1 at Johns Hopkins and will undergo DCFPyL PET/CT and 177Lu-PSMA dosimetry imaging only (single tracer dose). A feasibility analysis of dosimetry will be performed after meeting the accrual goal of Cohort 1 to determine if the study will proceed into Cohort 2. If Cohort 2 proceeds, based on the dosimetry analysis, the major requirements of the study are to undergo treatment with 177Lu-PNT2002, have bloodwork, physical exams, and imaging done at study-specific time points, and to answer questionnaires. Patients will be in the study for about two years after enrolling.

NCT ID: NCT06199453 Not yet recruiting - Clinical trials for Adenoid Cystic Carcinoma

The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients With ACC- an Open, Non-commercial Clinical Trial

LuRM_ACC/2023
Start date: January 2024
Phase: Phase 2
Study type: Interventional

Non-commercial phase 2 clinical trial to evaluate the effectiveness, safety and tolerability of treatment using prostate-specific membrane antigen (PSMA) labeled with 177Lutetium in patients with recurrence and/or metastases in adenoid cystic carcinoma originating from the salivary glands of the head and neck region. Patients with PSMA receptor expression confirmed by PET/CT after administration of 68Ga-PSMA I&T will be eligible for treatment.

NCT ID: NCT06118086 Recruiting - Clinical trials for Adenoid Cystic Carcinoma

Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Start date: December 20, 2023
Phase: Phase 1
Study type: Interventional

The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)

NCT ID: NCT05930951 Recruiting - Clinical trials for Adenoid Cystic Carcinoma of the Head and Neck

Study of OBT076 Associated or Not in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck

AdCC_2023-01
Start date: November 29, 2023
Phase: Phase 1
Study type: Interventional

Adenoid cystic carcinoma (AdCC) is a rare salivary gland malignant tumor that accounts for approximately 1-3% of all head and neck cancers. AdCC is often charaterised by a long natural history with a propensity for indolent but relentless growth and dissemination. Local recurrences and late distant metastases are common findings in about 35% of the patients and associated with a poor prognosis1. AdCC is among the most lethal salivary gland tumors2 with no proven therapy for metastatic disease. Little is known about endogenous immune response directed against AdCC. However, in a relatively large series of 28 AdCC tumor, the immune profiling has shown in most tumors high and frequent programmed death ligand 2 (PD-L2) expression and PD-L1 was generally not expressed on tumor and infiltrating cells3. The Antibody Drug Conjugates (ADCs) are emerging as a novel therapeutic option in cancer treatment that looks promising for solid tumors. An experimental CD205/Ly75-directed ADC, OBT076 induce potent cytotoxic and antitumor activity. Recently, the combination of immunohistochemistry (IHC) and tissue micro array (TMA) was performed in a series of 46 AdCC, showing a unique profile with both frequent and high expression of CD205/Ly75, much higher than for other solid tumors. In a phase I study, OBT076 demonstrated promising results for 3 patients with 2 partial responses and 1 complete response for a gastric cancer4. In this last patient, analysis showed an increase in PD1+, CD4+ and CD8+ cells suggesting that OBT076 activates the patient's immune response against the tumor, especially PD-1 targeted therapies4. Based on this rational and on the high level of expression of CD205/Ly75 in AdCC, the hypothesis tested in this study is that OBT076 could be a potential effective treatment for R/M AdCC, which is an orphan lethal disease. The efficacy of OBT076 will be tested either alone or followed by an anti PD-1 inhibitor (Balstilimab) with the hypothesis that OBT076 will induce immune infiltrate that could restore sentivity to PD-1 targeting.

NCT ID: NCT05774899 Recruiting - Clinical trials for Adenoid Cystic Carcinoma

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Start date: June 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to treat patients with NOTCH active advanced adenoid cystic carcinoma (ACC) tumors with a combination or two different oral medications to slow tumor growth and improve survival outcomes. The names of the study drugs involved in this study are: - CB-103 (an oral NOTCH pathway inhibitor) - Abemaciclib (CDK4/6 inhibitor) - Lenvatinib (a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI))

NCT ID: NCT05733910 Recruiting - Clinical trials for Head and Neck Cancer

Simultaneous Integrated Boost in Carbon Ion Radiotherapy for Head and Neck Adenoid Cystic Carcinoma

SIBACIRT
Start date: November 28, 2023
Phase: N/A
Study type: Interventional

The investigators aim at investigating in a prospective clinical trial whether using a Simoultaneous Integrated Boost of carbon ions treatment planning approach, improving the tumor dose conformation while lowering the unintended dose to the low-risk volume, can significantly reduce the probability of toxicity without affecting Local Control.

NCT ID: NCT05553782 Not yet recruiting - Clinical trials for Adenoid Cystic Carcinoma

Drug Screening Using Novel IMD in ACC and Salivary Cancers

Start date: November 1, 2023
Phase: Early Phase 1
Study type: Interventional

This research study is studying the effect of different drugs as possible treatments for adenoid cystic carcinoma (ACC), a type of head and neck cancer. The name of the study intervention involved in this study is: -implantable microdevice

NCT ID: NCT05499936 Recruiting - Clinical trials for Metastatic Adenoid Cystic Carcinoma

68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

This study was used to study the diagnostic value of 68Ga-FAPI, a novel fibroblast activating inhibitor, in metastatic adenoid cystic carcinoma(ACC)

NCT ID: NCT05377996 Recruiting - Breast Cancer Clinical Trials

A Study of XMT-1660 in Participants With Solid Tumors

Start date: August 15, 2022
Phase: Phase 1
Study type: Interventional

A Study of XMT-1660 in Solid Tumors